Skip to main content

New cardiovascular targets and innovative therapeutic strategies

RYC2020-028884-I

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Ramón y Cajal
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neutrophil β1 adrenergic receptor blockade blunts stroke-associated neuroinflammation

  • Clemente-Moragón, Agustín
  • Oliver, Eduardo
  • Calle, D.
  • Cussó, Lorena
  • Gómez Tech, Mónica
  • Pradillo, Jesús M.
  • Castejón, Raquel
  • Rallón, Norma
  • Benito, José Miguel
  • Fernández-Ferro, José C.
  • Carneado-Ruíz, Joaquín
  • Moro, María A.
  • Sánchez-González, Javier
  • Fuster, Valentín
  • Cortés-Canteli, Marta
  • Desco, Manuel
  • Ibáñez, Borja
39 p.-7 fig.-1 graph. abst., Background and Purpose Reperfusion therapy is the standard of care for ischemic stroke; however, there is a need to identify new therapeutic targets able to ameliorate cerebral damage. Neutrophil´s β1 adrenergic receptor (β1AR) has been linked to migration during exacerbated inflammation. Given the central role of neutrophils in cerebral damage during stroke, we hypothesize that β1AR blockade will improve stroke outcomes., Experimental Approach Rats were subjected to middle cerebral artery occlusion–reperfusion to evaluate the effect on stroke of the selective β1AR blocker metoprolol (12.5 mg/Kg) when injected i.v. 10 min before reperfusion., Key Results Magnetic resonance imaging and histopathology analysis showed that pre-reperfusion i.v. metoprolol reduced IS. This was accompanied by reduced cytotoxic edema at 24 h and vasogenic edema at 7 d. Metoprolol-treated rats showed reduced brain neutrophil infiltration and those which infiltrated displayed a high proportion of anti-inflammatory phenotype (N2, YM1+). Additional inflammatory models demonstrated that metoprolol specifically blocked neutrophil migration via β1AR and excluded a significant effect on glia compartment. Consistently, metoprolol did not protect the brain in neutrophil-depleted rats upon stroke. In patients suffering an ischemic stroke, β1AR blockade by metoprolol reduced circulating neutrophil–platelet co-aggregates., Conclusions and Implications Our findings describe that β1AR blockade ameliorates cerebral damage by targeting neutrophils, identifying a novel therapeutic target to improve outcomes in patients with stroke. This therapeutic strategy is in the earliest stages of the translational pathway and should be further explored., This study received funding from the Instituto de Salud Carlos III (ISCIII; PI16/02110 to B.I and PT20/00044 to MD), the European Regional Development Fund (ERDF) “A way of making Europe", the Comunidad de Madrid (S2017/BMD-3867 RENIM-CM to MD and BI) cofunded with European structural and investment funds and by Agencia Estatal de Investigación (PID2019‐110369RB‐I00 to B.I). BI is a recipient of funding from the European Research Council (ERC) under the European Union Horizon 2020 Research and Innovation Programme (ERC-Consolidator Grant agreement No. 819775). EO is a recipient of funds from the Comunidad de Madrid Programa de Atracción de Talento (2017-T1/BMD 5185) and from a Ramón y Cajal grant (RYC2020-028884-I) funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”. ACM is the beneficiary of an FPU fellowship from the Ministerio de Ciencia e Innovación (FPU2017/01932). MCC is the beneficiary of a Miguel Servet contract (MS16/00174). The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovación and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension

  • Martín de Miguel, Irene
  • Cruz Utrilla, Alejandro
  • Oliver, Eduardo
  • Escribano-Subias, Pilar
Pulmonary arterial hypertension (PAH) is a severe condition with a high mortality rate despite advances in diagnostic and therapeutic strategies. In recent years, significant scientific progress has been made in the understanding of the underlying pathobiological mechanisms. Since current available treatments mainly target pulmonary vasodilation, but lack an effect on the pathological changes that develop in the pulmonary vasculature, there is need to develop novel therapeutic compounds aimed at antagonizing the pulmonary vascular remodeling. This review presents the main molecular mechanisms involved in the pathobiology of PAH, discusses the new molecular compounds currently being developed for the medical treatment of PAH and assesses their potential future role in the therapeutic algorithms of PAH., Eduardo Oliver is a recipient of funds from Proyectos de Generación de Conocimiento (PID2021-123167OB-I00) and from a Ramón y Cajal grant (RYC2020-028884-I) funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future”. P.E-S. has received research grants from Janssen., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of UCP2 in the energy metabolism of the cancer cell line A549

  • Segalés, Jessica
  • Sánchez-Martín, Carlos
  • Pujol, Aleida
  • Martín-Ruiz, Marta
  • De los Santos, Patricia
  • Lobato-Alonso, Daniel
  • Oliver, Eduardo
  • Rial, Eduardo
12 p.-5 fig., The uncoupling protein UCP2 is a mitochondrial carrier for which transport activity remains controversial. The physiological contexts in which UCP2 is expressed have led to the assumption that, like UCP1, it uncouples oxidative phosphorylation and thereby reduces the generation of reactive oxygen species. Other reports have involved UCP2 in the Warburg effect, and results showing that UCP2 catalyzes the export of matrix C4 metabolites to facilitate glutamine utilization suggest that the carrier could be involved in the metabolic adaptations required for cell proliferation. We have examined the role of UCP2 in the energy metabolism of the lung adenocarcinoma cell line A549 and show that UCP2 silencing decreased the basal rate of respiration, although this inhibition was not compensated by an increase in glycolysis. Silencing did not lead to either changes in proton leakage, as determined by the rate of respiration in the absence of ATP synthesis, or changes in the rate of formation of reactive oxygen species. The decrease in energy metabolism did not alter the cellular energy charge. The decreased cell proliferation observed in UCP2-silenced cells would explain the reduced cellular ATP demand. We conclude that UCP2 does not operate as an uncoupling protein, whereas our results are consistent with its activity as a C4-metabolite carrier involved in the metabolic adaptations of proliferating cells., This research was funded by grants (SAF2010-20256, PID2019-108166GB-I00, and Redox Biology and Medicine Network RED2018-102576-T to E.R. and PID2021-123167OB-I00 and a Ramón y Cajal RYC2020-028884-I to E.O.) from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033). P.d.l.S. was supported by a Garantía Juvenil contract of the Comunidad de Madrid (PEJ-2020-TL/BMD-18670). D.L.-A. was funded by the Programa Investigo from the Comunidad de Madrid and European Union-Next Generation EU (09-PIN1-00004.3/2022)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Oxidative Post-translational Protein Modifications upon Ischemia/Reperfusion Injury

  • Binek, Aleksandra
  • Castans, Celia
  • Jorge, Inmaculada
  • Bagwan, Navratan
  • Rodríguez, José Manuel
  • Fernández-Jiménez, Rodrigo
  • Galán-Arriola, Carlos
  • Oliver, Eduardo
  • Gómez, Mónica
  • Clemente-Moragón, Agustín
  • Ibáñez, Borja
  • Camafeita, Emilio
  • Vázquez, Jesús
While reperfusion, or restoration of coronary blood flow in acute myocardial infarction, is a requisite for myocardial salvage, it can paradoxically induce a specific damage known as ischemia/reperfusion (I/R) injury. Our understanding of the precise pathophysiological molecular alterations leading to I/R remains limited. In this study, we conducted a comprehensive and unbiased time-course analysis of post-translational modifications (PTMs) in the post-reperfused myocardium of two different animal models (pig and mouse) and evaluated the effect of two different cardioprotective therapies (ischemic preconditioning and neutrophil depletion). In pigs, a first wave of irreversible oxidative damage was observed at the earliest reperfusion time (20 min), impacting proteins essential for cardiac contraction. A second wave, characterized by irreversible oxidation on different residues and reversible Cys oxidation, occurred at late stages (6–12 h), affecting mitochondrial, sarcomere, and inflammation-related proteins. Ischemic preconditioning mitigated the I/R damage caused by the late oxidative wave. In the mouse model, the two-phase pattern of oxidative damage was replicated, and neutrophil depletion mitigated the late wave of I/R-related damage by preventing both Cys reversible oxidation and irreversible oxidation. Altogether, these data identify protein PTMs occurring late after reperfusion as an actionable therapeutic target to reduce the impact of I/R injury., This study was supported by competitive grants from the MCIN/AEI/10.13039/501100011033/ and FEDER Una manera de hacer Europa (PID2021-122348NB-I00 and PID2022-140176OB-I00), the MCIN/AEI/10.13039/501100011033 the Unión Europea NextGenerationEU/PRTR (PLEC2022-009235, and PLEC2022-009298), the Comunidad de Madrid (Programa S2022/BDM-7333-CM, INMUNO-VAR, P2022/BMD-7333, and RENIM-CM, P2022/BMD-7403), “la Caixa” Banking Foundation (HR17-00247, LCF/PR/HP22/52320018, and LCF/PR/HR22/52420019), and the European Commission (ERC Consolidator Grant “MATRIX”, 819775). Rodrigo Fernandez-Jimenez is the recipient of grant PI22/01560 funded by the ISCIII-Fondo de Investigación Sanitaria and co-funded by the European Union. Aleksandra Binek and Navratan Bagwan were FP7-PEOPLE-2013-ITN-Cardionext fellows from the European Union’s Seventh Framework Programme (Marie Curie Actions). Celia Castans holds a Formación del Profesorado Universitario (FPU14/05292) fellowship from the Spanish Ministry of Education, Culture and Sports. Eduardo Oliver holds a Ramón y Cajal fellowship (RYC2020-028884-I) and granted by the MCIN/AEI/10.13039/501100011033/ and FEDER Una manera de hacer Europa (PID2021-133167OB-100) and by “ESF Investing in your future”. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S)., Peer reviewed